3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
INDUSTRY
2
NETWORK
1
Study Type
Observational
2
Sponsor
Cancer Type
Plasma cell
2
Genitourinary
2
Breast
2
Sarcoma
1
Conditions
Prostatic Neoplasms
2
Multiple Myeloma
2
Breast Neoplasms
2
Patient Compliance
1
Osteolysis
1
Bone Neoplasms
1
Interventions
pembrolizumab
164
Prednisone
130
enzalutamide
127
Docetaxel
122
Abiraterone Acetate
95
Nivolumab
93
Gemcitabine
71
Sunitinib
67
atezolizumab
50
abiraterone
50
Leuprolide
49
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
48
Cisplatin
48
radium Ra 223 dichloride
39
Sorafenib
39
darolutamide
38
apalutamide
38
Ipilimumab
38
Carboplatin
37
Prednisolone
33
Everolimus
33
Axitinib
32
cabozantinib
31
avelumab
31
pazopanib
30
Bevacizumab
30
Paclitaxel
29
enfortumab vedotin
28
bicalutamide
28
Cyclophosphamide
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Clodronic Acid
×
Genitourinary
×
Clear all
NCT01198457
2012-09-07
BONA
Bayer
Completed
147 enrolled
NCT00909142
2012-04-06
BICAM
Bayer
Completed
149 enrolled